Answers are grounded in this paper and cite their sources.
Anemia of renal disease is common and is associated with significant morbidity and death. It is mainly caused by a decrease in erythropoietin production in the kidneys and can be partially corrected with erythropoiesis-stimulating agents (ESAs). However, randomized controlled trials have shown that using ESAs to target normal hemoglobin levels can be harmful, and have called into question any benefits of ESA treatment other than avoidance of transfusions.
No takes yet. Share an insight, caveat, or question.
Nakhoul et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: